

ForPatients

by Roche

Acute Kidney Injury

A Study to Evaluate the Efficacy and Safety of GDC-8264 in Preventing Cardiac Surgery-Associated Acute Kidney Injury (AKI) and Major Adverse Kidney Events (MAKE)

Trial Status

Not Yet Recruiting

Trial Runs In

0 Countries

Trial Identifier

NCT06602453 2024-513125-23-00
GC45428

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

The aim of this study is to evaluate the efficacy and safety of GDC-8264 compared with placebo in participants undergoing cardiac surgery who are determined to be at moderate to high risk of developing AKI and subsequent MAKE at 90 days after surgery (MAKE90). The study will be performed in two parts- Part 1 and Part 2.

Genentech, Inc.

Sponsor

Phase 2

Phase

NCT06602453 2024-513125-23-00 GC45428

Trial Identifiers

Eligibility Criteria:

Gender

All

Age

>=40 Years

Healthy Volunteers

No